Loading
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
Previous close
$9.62
+$0.04 · +0.42%
Pre-market
$9.63
+$0.01 · +0.10%
Sep 8, 4:07 AM ET
Regular session · ET · Market data may be delayed.
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
Day range
Current $9.62
52-week range
Current $9.62
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
81
Deep Value
Sentiment
68
Bullish
Risk
51
Elevated Risk
Momentum
28
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
Day range
Current $9.62
52-week range
Current $9.62
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 510.17M USD | 426.45M USD | 258.22M USD | 154.08M USD | 80.94M USD |
| Cost of goods sold | 217.41M USD | 206.9M USD | 169.27M USD | 118.82M USD | 79.77M USD |
| Gross profit | 292.77M USD | 219.55M USD | 88.94M USD | 35.27M USD | 1.17M USD |
| Research and development | 4.76M USD | 1.81M USD | 3.3M USD | 3.61M USD | 3.65M USD |
| Selling, general, and administrative | 91.58M USD | 74.12M USD | 59.02M USD | 52.46M USD | 42.9M USD |
| Operating expenses | 101.32M USD | 80.57M USD | 67.31M USD | 74.63M USD | 59.55M USD |
| Interest income | 1.87M USD | 2.1M USD | 1.62M USD | 44.83K USD | 34.53K USD |
| Interest expense | 7.11M USD | 13.93M USD | 25.03M USD | 19.28M USD | 13.06M USD |
| Depreciation and amortization | 8.1M USD | 8.05M USD | 8.33M USD | 7.11M USD | 5.5M USD |
| Operating income | 191.44M USD | 138.98M USD | 21.63M USD | −39.37M USD | −58.37M USD |
| Net income | 146.93M USD | 197.67M USD | −28.24M USD | −65.9M USD | −71.65M USD |
Company facts updated Sep 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$18.67
94.07% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR131.63M0.12%109.96B USD0.06%$145.34+0.37%
First Trust NYSE Arca Biotechnology Index FundFBT95.92M3.25%2.95B USD0.55%$270.93-1.04%
State Street SPDR S&P Biotech ETFXBI79.39M0.69%11.49B USD0.35%$163.81-0.35%
Vanguard Morningstar Total Stock Market ETFVTI59.66M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM56.51M0.07%80.51B USD0.19%$296.01+0.28%
Vanguard Extended Market ETFVXF22.54M0.02%93.7B USD0.05%$242.66+0.14%
Vanguard Morningstar Small-Cap ETFVB21.4M0.01%183.4B USD0.03%$300.01+0.05%
iShares Russell 2000 Growth ETFIWO20.59M0.14%14.7B USD0.24%$377.54+0.12%iShares Core S&P Small-Cap ETFIJRFirst Trust NYSE Arca Biotechnology Index FundFBTState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 Growth ETFIWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
